Lung Cancer Organoids and Patient Derived Tumor Xenografts
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMaastricht Radiation Oncology
About this trial
Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients selected to undergo primary surgical resection of a primary lung cancer. All types of resection are eligible, e.g. wedge resection, segmental resection, lobectomy, pneumonectomy.
All patients with (suspected) lung cancer that will undergo a bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy.
Disqualifiers
None
Trial population
Patients with lung cancer
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Tissue and blood
Other interventionTissue and blood will be derived from patient during a standard of care procedure
Treatment groups
600 Participants
are divided into 1 treatment groupGroup A: All patiens1 intervention
Trial outcomes
Primary outcomes
1
Lung cancer organoids
Establishing matched normal and primary human lung cancer organoids from patient-derived (tumor) tissue material by establishing long term culturing and bio-banking conditions for matched normal and primary lung cancer organoids from patient-derived lung (tumor) material. From these, we will In the established organoids we will: • the rate of proliferation and cell death (turnover) will be calculated
Time frame
1 year2
Lung cancer organoids
Establishing matched normal and primary human lung cancer organoids from patient-derived (tumor) tissue material by establishing long term culturing and bio-banking conditions for matched normal and primary lung cancer organoids from patient-derived lung (tumor) material. From these, we will In the established organoids we will: • the size distribution of the organoids
Time frame
1 year3
Lung cancer organoids
Establishing matched normal and primary human lung cancer organoids from patient-derived (tumor) tissue material by establishing long term culturing and bio-banking conditions for matched normal and primary lung cancer organoids from patient-derived lung (tumor) material. From these, we will In the established organoids we will: • determine the frequency of primary, secondary and tertiary organoid formation
Time frame
1 yearSecondary outcomes
1
Oncogenetic drivers
To define oncogenic drivers in lung cancer organoids
Time frame
1 year2
Tumor heterogeneity
To investigate the stability of (epi-) genetic and phenotypic tumor heterogeneity of cultured organoids compared to a primary/secondary biopsy
Time frame
1 year3
Molecular biology
To predict sensitivity and to get insight in the molecular biology of the response to immunotherapy, radiotherapy, cytotoxic and targeted agents
Time frame
1 year4
Treatment response
To compare treatment response in normal lung organoids and lung cancer organoids
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov